For this reason, GOLPH3 has been postulated as biomarker of tumor progression for a variety of cancer types, including breast cancer [27], oral tongue cancer [28], glioblastoma multiforme [29], prostate cancer [30], esophageal squamous cell carcinoma [31], gastric cancer [32], renal cell carcinoma [33], hepatocellular carcinoma [34], non-small cell lung cancer [35], pancreatic ductal adenocarcinoma [36], epithelial ovarian carcinoma [37], bladder cancer [38], colorectal cancer [39], and melanoma [40]. This evidence concerns the gene GOLPH3 and breast carcinoma.